vs
Side-by-side financial comparison of Laird Superfood, Inc. (LSF) and Protalix BioTherapeutics, Inc. (PLX). Click either name above to swap in a different company.
Laird Superfood, Inc. is the larger business by last-quarter revenue ($13.3M vs $9.1M, roughly 1.5× Protalix BioTherapeutics, Inc.). Laird Superfood, Inc. runs the higher net margin — -13.2% vs -60.3%, a 47.2% gap on every dollar of revenue. On growth, Laird Superfood, Inc. posted the faster year-over-year revenue change (15.0% vs -49.9%). Over the past eight quarters, Laird Superfood, Inc.'s revenue compounded faster (16.1% CAGR vs -6.7%).
Laird Superfood, Inc. develops, manufactures and sells a portfolio of plant-based functional superfood products, including premium coffee creamers, hydration blends, nutritional supplements, and plant-powered snacks. It serves health-conscious consumers through direct-to-consumer e-commerce platforms and offline retail partners, mainly operating in the North American market with a focus on sustainably sourced clean ingredients.
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
LSF vs PLX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $13.3M | $9.1M |
| Net Profit | $-1.8M | $-5.5M |
| Gross Margin | 34.1% | 49.4% |
| Operating Margin | -13.5% | -51.1% |
| Net Margin | -13.2% | -60.3% |
| Revenue YoY | 15.0% | -49.9% |
| Net Profit YoY | -341.4% | -184.8% |
| EPS (diluted) | — | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $13.3M | $9.1M | ||
| Q3 25 | $12.9M | $17.9M | ||
| Q2 25 | $12.0M | $15.7M | ||
| Q1 25 | $11.7M | $10.1M | ||
| Q4 24 | $11.6M | $18.2M | ||
| Q3 24 | $11.8M | $18.0M | ||
| Q2 24 | $10.0M | $13.5M | ||
| Q1 24 | $9.9M | — |
| Q4 25 | $-1.8M | $-5.5M | ||
| Q3 25 | $-975.1K | $2.4M | ||
| Q2 25 | $-362.2K | $164.0K | ||
| Q1 25 | $-156.2K | $-3.6M | ||
| Q4 24 | $-398.4K | $6.5M | ||
| Q3 24 | $-166.1K | $3.2M | ||
| Q2 24 | $-239.1K | $-2.2M | ||
| Q1 24 | $-1.0M | — |
| Q4 25 | 34.1% | 49.4% | ||
| Q3 25 | 36.5% | 53.4% | ||
| Q2 25 | 39.9% | 62.5% | ||
| Q1 25 | 41.9% | 19.1% | ||
| Q4 24 | 38.6% | 78.7% | ||
| Q3 24 | 43.0% | 53.4% | ||
| Q2 24 | 41.8% | 29.8% | ||
| Q1 24 | 40.0% | — |
| Q4 25 | -13.5% | -51.1% | ||
| Q3 25 | -7.7% | 11.9% | ||
| Q2 25 | -3.3% | 7.5% | ||
| Q1 25 | -1.9% | -41.0% | ||
| Q4 24 | -4.1% | 39.6% | ||
| Q3 24 | -2.3% | 22.2% | ||
| Q2 24 | -3.4% | -18.0% | ||
| Q1 24 | -11.0% | — |
| Q4 25 | -13.2% | -60.3% | ||
| Q3 25 | -7.6% | 13.2% | ||
| Q2 25 | -3.0% | 1.0% | ||
| Q1 25 | -1.3% | -35.8% | ||
| Q4 24 | -3.4% | 35.6% | ||
| Q3 24 | -1.4% | 18.0% | ||
| Q2 24 | -2.4% | -16.4% | ||
| Q1 24 | -10.3% | — |
| Q4 25 | — | $-0.06 | ||
| Q3 25 | — | $0.03 | ||
| Q2 25 | — | $0.00 | ||
| Q1 25 | — | $-0.05 | ||
| Q4 24 | — | $0.10 | ||
| Q3 24 | — | $0.03 | ||
| Q2 24 | — | $-0.03 | ||
| Q1 24 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $5.1M | $14.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $11.5M | $48.2M |
| Total Assets | $19.2M | $82.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $5.1M | $14.7M | ||
| Q3 25 | $5.1M | $13.6M | ||
| Q2 25 | $3.9M | $17.9M | ||
| Q1 25 | $7.0M | $19.5M | ||
| Q4 24 | $8.3M | $19.8M | ||
| Q3 24 | $7.9M | $27.4M | ||
| Q2 24 | $7.6M | $23.4M | ||
| Q1 24 | $7.1M | — |
| Q4 25 | $11.5M | $48.2M | ||
| Q3 25 | $12.8M | $52.9M | ||
| Q2 25 | $13.4M | $49.9M | ||
| Q1 25 | $13.3M | $45.2M | ||
| Q4 24 | $13.2M | $43.2M | ||
| Q3 24 | $13.1M | $32.4M | ||
| Q2 24 | $12.6M | $28.6M | ||
| Q1 24 | $12.7M | — |
| Q4 25 | $19.2M | $82.3M | ||
| Q3 25 | $18.9M | $82.3M | ||
| Q2 25 | $20.4M | $78.5M | ||
| Q1 25 | $21.5M | $73.9M | ||
| Q4 24 | $19.3M | $73.4M | ||
| Q3 24 | $18.8M | $61.6M | ||
| Q2 24 | $18.0M | $91.5M | ||
| Q1 24 | $17.6M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $68.4K | $2.0M |
| Free Cash FlowOCF − Capex | — | $1.6M |
| FCF MarginFCF / Revenue | — | 17.8% |
| Capex IntensityCapex / Revenue | — | 4.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-13.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $68.4K | $2.0M | ||
| Q3 25 | $1.2M | $-3.7M | ||
| Q2 25 | $-2.8M | $-5.2M | ||
| Q1 25 | $-1.3M | $-5.1M | ||
| Q4 24 | $339.2K | $4.0M | ||
| Q3 24 | $305.8K | $4.1M | ||
| Q2 24 | $642.7K | $-3.6M | ||
| Q1 24 | $-422.3K | — |
| Q4 25 | — | $1.6M | ||
| Q3 25 | — | $-4.2M | ||
| Q2 25 | — | $-5.7M | ||
| Q1 25 | — | $-5.4M | ||
| Q4 24 | — | $3.6M | ||
| Q3 24 | — | $4.0M | ||
| Q2 24 | — | $-3.8M | ||
| Q1 24 | — | — |
| Q4 25 | — | 17.8% | ||
| Q3 25 | — | -23.7% | ||
| Q2 25 | — | -36.2% | ||
| Q1 25 | — | -53.0% | ||
| Q4 24 | — | 19.6% | ||
| Q3 24 | — | 22.4% | ||
| Q2 24 | — | -28.1% | ||
| Q1 24 | — | — |
| Q4 25 | — | 4.4% | ||
| Q3 25 | — | 2.8% | ||
| Q2 25 | — | 2.8% | ||
| Q1 25 | — | 3.0% | ||
| Q4 24 | — | 2.3% | ||
| Q3 24 | — | 0.5% | ||
| Q2 24 | — | 1.3% | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -1.58× | ||
| Q2 25 | — | -31.91× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.61× | ||
| Q3 24 | — | 1.27× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LSF
| Wholesale | $7.0M | 52% |
| Coffee Tea And Hot Chocolate Products | $4.4M | 33% |
| Hydration And Beverage Enhancing Supplements | $1.6M | 12% |
| Other | $352.6K | 3% |
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
